Industry Session
16:00-16:30
Pioneering innovation in FcRn-Targeted Therapies: Advancing Neuroimmunology and Autoimmune Diseases Treatments
Silvia Rossi – Director Medical Affairs and Evidence Generation, Argenx
16:30-17:00
Ocrelizumab subcutaneous, a new option for patients
Juan Acosta – Global Medical Scientific Leader Multiple Sclerosis, Roche
17:00-17:30
ITAKOS: an observational Italian study on ofatumumab with a new exploratory endpoint
Renato Turrini- Medical Head Neurosciences, Novartis
17:30 – 18:00
Advancements in neurology
Margaret Mary Mondino – Medical Lead Multiple Sclerosis, Sanofi
Event Timeslots (1)
Day 1 – Mon, May 5th
-
© 2025 AINI — Associazione Italiana Neuroimmunologia. All rights reserved.
Powered by EEM Services